2-(4-METHYLPHENOXY)-5-(TRIFLUOROMETHYL)ANILINE
- $205 - $802.73
- Product name: 2-(4-METHYLPHENOXY)-5-(TRIFLUOROMETHYL)ANILINE
- CAS: 16824-50-3
- MF: C14H12F3NO
- MW: 267.25
- EINECS:
- MDL Number:MFCD00018054
- Synonyms:AKOS B033354;2-(4-METHYLPHENOXY)-5-(TRIFLUOROMETHYL)ANILINE;Benzenamine, 2-(4-methylphenoxy)-5-(trifluoromethyl)-;2-(P-tolyloxy)-5-(trifluoromethyl)aniline
3 prices
Selected condition:
Brand
- American Custom Chemicals Corporation
- Crysdot
- Matrix Scientific
Package
- 500MG
- 5g
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberHCH0042679
- Product description2-(4-METHYLPHENOXY)-5-(TRIFLUOROMETHYL)ANILINE 95.00%
- Packaging500MG
- Price$802.73
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD12134893
- Product description2-(p-Tolyloxy)-5-(trifluoromethyl)aniline 95+%
- Packaging5g
- Price$648
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number022083
- Product description2-(4-Methylphenoxy)-5-(trifluoromethyl)aniline
- Packaging500mg
- Price$205
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
American Custom Chemicals Corporation | HCH0042679 | 2-(4-METHYLPHENOXY)-5-(TRIFLUOROMETHYL)ANILINE 95.00% | 500MG | $802.73 | 2021-12-16 | Buy |
Crysdot | CD12134893 | 2-(p-Tolyloxy)-5-(trifluoromethyl)aniline 95+% | 5g | $648 | 2021-12-16 | Buy |
Matrix Scientific | 022083 | 2-(4-Methylphenoxy)-5-(trifluoromethyl)aniline | 500mg | $205 | 2021-12-16 | Buy |
Properties
Boiling point :314.1±42.0 °C(Predicted)
Density :1.260±0.06 g/cm3(Predicted)
pka :3.24±0.10(Predicted)
Density :1.260±0.06 g/cm3(Predicted)
pka :3.24±0.10(Predicted)
Safety Information
Symbol(GHS): | |||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Danger | ||||||||||||||||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||||||||||||||||
Precautionary statements: |
|